Author (year)
Study design
Study group
Duration (month) Gender M/F Sample size Orlistat/ Control
Age (year)
Other intervention (Study group)
Notes about subjects
B. Guy-Grand (2004
randomized, double-blind placebo-controlled parallel-group clinical trial
120 mg(tid) placebo
6
M/F
458/458
18–65
mildly reduced-calorie diet
obese patients (BMI 28–40 kg/m2) untreated type 2 diabetes untreated hypertension hypercholesterolemia
T. P. Didangelos (2004)
randomized open-label prospective multicenter parallel-group controlled clinical trial
360 mg/day control
6
M/F
94/32
30–72
hypocaloric diet (HCD) (500 calories below the needs(mean daily calorie intake 1300)
type 2 DM treated with oral antidiabetic agents (metformin alone or in combination with sulfonylureas) All patients had the MetSyn
Giuseppe Cocco (2005)
randomized double blind placebo-controlled parallel-group clinical trial
120 mg(tid) placebo
6
M/F
45/45
at least 35
standardized physical program(walk briskly for at least 30 min per day) +fat-restricted diet adipose patients (BMI 31-40kg/m2) metabolic syndrome,diabetes type 2 hypertension treated with drug coronary heart disease concomitant cardiac dysfunction Antidiabetic drugs
T. D. Filippatos (2005)
randomized open-label parallel-group clinical trial
120 mg(tid) control
3
M/F
28/29
53 ± 11
micronised fenofibrate 200 mg/day + low-calorie low-fat diet (500–1000 kcal reduction in daily energy)
Overweight and obese (BMI > 28 kg/m2) ,MetS
E. S. Nakou (2008)
randomized open-label parallel-group clinical trial
120 mg(tid) control
6
M/F
29/28
55 ± 10
ezetimibe 10 mg/day+ low-fat low-calorie diet BMI>28 kg/m2 hypercholesterolemia antihypertensive drugs on a stabilised dose for at least 8 weeks before entry to the study
Jinghua Song (2018)
randomized open-label parallel-group clinical trial
120 mg(tid) control
3
F
60/60
18–40
Diane-35+individualized low-fat diet and moderate daily physical activity
PCOS BMI> 24 kg/m2
120 mg(tid) control
F
60/60
metformin(500mg/day for the first week/500mg twice daily for the next week) +Diane-35 (OMD group)+ individualized low-fat diet and moderate daily physical activity
Junzhao Ye (2019)
randomized open-label parallel-group clinical trial
120 mg(tid) control
6
M/F
ITT 68/102
18 - 60
without additional treatment Obese BMI> 25 kg/m2 NAFLD no history of use of medication associated with obesity
120 mg(tid) control
M/F
PPA 54/76